| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8828427 | CELGENE | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Jun, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8673939 | CELGENE | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
May, 2023
(4 months ago) | |
| US8735428 | CELGENE | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
May, 2023
(4 months ago) | |
|
US8735428 (Pediatric) | CELGENE | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Nov, 2023
(a month from now) | |
|
US8673939 (Pediatric) | CELGENE | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Nov, 2023
(a month from now) | |
| US8198262 | CELGENE | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Jun, 2025
(1 year, 8 months from now) | |
|
US8198262 (Pediatric) | CELGENE | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Dec, 2025
(2 years from now) | |
| US9993467 | CELGENE | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
May, 2030
(6 years from now) | |
| US10555939 | CELGENE | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
May, 2030
(6 years from now) | |
|
US9993467 (Pediatric) | CELGENE | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Nov, 2030
(7 years from now) | |
|
US10555939 (Pediatric) | CELGENE | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Nov, 2030
(7 years from now) | |
|
US8828427 (Pediatric) | CELGENE | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Dec, 2031
(8 years from now) | |
Pomalyst is owned by Celgene.
Pomalyst contains Pomalidomide.
Pomalyst has a total of 12 drug patents out of which 2 drug patents have expired.
Expired drug patents of Pomalyst are:
- US8673939
- US8735428
Pomalyst was authorised for market use on 08 February, 2013.
Pomalyst is available in capsule;oral dosage forms.
Pomalyst can be used as use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on or within 60 days of completing the last therapy; use of pomalidomide for the treatment of multiple myeloma, use of pomalidomide for the treatment of multiple myeloma; use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on or within 60 days of completing the last therapy.
The generics of Pomalyst are possible to be released after 21 December, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M (M) | Nov 20, 2023 |
| Orphan Drug Exclusivity (ODE) | May 14, 2027 |
| Pediatric Exclusivity (PED) | Nov 14, 2027 |
Drugs and Companies using POMALIDOMIDE ingredient
Market Authorisation Date: 08 February, 2013
Treatment: Use of pomalidomide for the treatment of multiple myeloma; Use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a pro...
Dosage: CAPSULE;ORAL
POMALYST family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic